GMP production and characterization of leucine zipper-tagged tumor necrosis factor-related apoptosis-inducing ligand (LZ-TRAIL) for phase i clinical trial

European Journal of Pharmacology

Volumn 740, Issue , 2014, Pages 722-732

  Jiang, Jing ^a   Liu, Xiaobin ^b   Deng, Leixiu ^b   Zhang, Peipei ^b   Wang, Guangjun ^b   Wang, Shifu ^b   Liu, Honghao ^b   Su, Yunpeng ^c  

^a BINZHOU MEDICAL UNIVERSITY   (China)

^b Shandong Simcere Medgenn Biopharmaceutical Co Ltd   (China)

^c Simcere Pharmaceutical Group   (China)

Author keywords

Anticancer; Escherichia coli; Leucine zipper; Preclinical; Safety; TRAIL

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; LEUCINE ZIPPER PROTEIN TAGGED TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; HYBRID PROTEIN; LZ-TRAIL PROTEIN, RECOMBINANT; MEMBRANE PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIUM CULTURE; BILIRUBIN BLOOD LEVEL; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG PURIFICATION; DRUG SAFETY; DRUG STABILITY; DRUG STERILITY; DRUG SYNTHESIS; ESCHERICHIA COLI; ESCHERICHIA COLI BL21; FERMENTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; LIVER TOXICITY; MACACA FASCICULARIS; MASS SPECTROMETRY; MOUSE; NONHUMAN; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL CULTURE; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENETICS; LIVER CELL; METABOLISM; NEOPLASMS; NUDE MOUSE; PATHOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; CLINICAL TRIALS, PHASE I AS TOPIC; ESCHERICHIA COLI; FEMALE; HEPATOCYTES; HUMANS; MACACA FASCICULARIS; MEMBRANE GLYCOPROTEINS; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; RECOMBINANT FUSION PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR BURDEN; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919342125     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.06.002     Document Type: Article

References (37)

1. C. Adams, K. Totpal, D. Lawrence, S. Marsters, R. Pitti, S. Yee, S. Ross, L. Deforge, H. Koeppen, M. Sagolla, D. Compaan, H. Lowman, S. Hymowitz, and A. Ashkenazi Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5 Cell Death Differ. 15 2008 751 761
2. A. Ashkenazi, P. Holland, and S.G. Eckhardt Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL) J. Clin. Oncol. 26 2008 3621 3630
3. A. Ashkenazi, R.C. Pai, S. Fong, S. Leung, D.A. Lawrence, S.A. Marsters, C. Blackie, L. Chang, A.E. McMurtrey, A. Hebert, L. DeForge, I.L. Koumenis, D. Lewis, L. Harris, J. Bussiere, H. Koeppen, Z. Shahrokh, and R.H. Schwall Safety and antitumor activity of recombinant soluble Apo2 ligand J. Clin. Invest. 104 1999 155 162
4. J.L. Bodmer, P. Meier, J. Tschopp, and P. Schneider Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL J. Biol. Chem. 275 2000 20632 20637
5. D.R. Camidge Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors Expert Opin. Biol. Ther. 8 2008 1167 1176
6. C. Falschlehner, C.H. Emmerich, B. Gerlach, and H. Walczak TRAIL signalling: decisions between life and death Int. J. Biochem. Cell Biol. 39 2007 1462 1475
7. A. Forero-Torres, J. Shah, T. Wood, J. Posey, R. Carlisle, C. Copigneaux, F.R. Luo, S. Wojtowicz-Praga, I. Percent, and M. Saleh Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5) Cancer Biother. Radiopharm. 25 2010 13 19
8. T.M. Ganten, R. Koschny, J. Sykora, H. Schulze-Bergkamen, P. Buchler, T.L. Haas, M.B. Schader, A. Untergasser, W. Stremmel, and H. Walczak Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs Clin. Cancer Res. 12 2006 2640 2646
9. C. Gasparini, L. Vecchi Brumatti, L. Monasta, and G. Zauli TRAIL-based therapeutic approaches for the treatment of pediatric malignancies Curr. Med. Chem. 20 2013 2254 2271
10. T. Hehlgans, and K. Pfeffer The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games Immunology 115 2005 1 20
11. R.S. Herbst, S.G. Eckhardt, R. Kurzrock, S. Ebbinghaus, P.J. ODwyer, M.S. Gordon, W. Novotny, M.A. Goldwasser, T.M. Tohnya, B.L. Lum, A. Ashkenazi, A.M. Jubb, and D.S. Mendelson Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer J. Clin. Oncol. 28 2010 2839 2846
12. S.J. Hotte, H.W. Hirte, E.X. Chen, L.L. Siu, L.H. Le, A. Corey, A. Iacobucci, M. MacLean, L. Lo, N.L. Fox, and A.M. Oza A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies Clin. Cancer Res. 14 2008 3450 3455
13. M. Jo, T.H. Kim, D.W. Seol, J.E. Esplen, K. Dorko, T.R. Billiar, and S.C. Strom Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand Nat. Med. 6 2000 564 567
14. S.K. Kelley, L.A. Harris, D. Xie, L. Deforge, K. Totpal, J. Bussiere, and J.A. Fox Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety J. Pharmacol. Exp. Ther. 299 2001 31 38
15. T.H. Kim, Y.G. Jo, H.H. Jiang, S.M. Lim, Y.S. Youn, S. Lee, X. Chen, Y. Byun, and K.C. Lee PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting J. Control Release 162 2012 422 428
16. T.H. Kim, Y.S. Youn, H.H. Jiang, S. Lee, X. Chen, and K.C. Lee PEGylated TNF-related apoptosis-inducing ligand (TRAIL) analogues: pharmacokinetics and antitumor effects Bioconjugate Chem. 22 2011 1631 1637
17. D. Lawrence, Z. Shahrokh, S. Marsters, K. Achilles, D. Shih, B. Mounho, K. Hillan, K. Totpal, L. DeForge, P. Schow, J. Hooley, S. Sherwood, R. Pai, S. Leung, L. Khan, B. Gliniak, J. Bussiere, C.A. Smith, S.S. Strom, S. Kelley, J.A. Fox, D. Thomas, and A. Ashkenazi Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions Nat. Med. 7 2001 383 385
18. M. Leverkus, M.R. Sprick, T. Wachter, A. Denk, E.B. Brocker, H. Walczak, and M. Neumann TRAIL-induced apoptosis and gene induction in HaCaT keratinocytes: differential contribution of TRAIL receptors 1 and 2 J. Invest. Dermatol. 121 2003 149 155
19. D. Mahalingam, C.N. Oldenhuis, E. Szegezdi, F.J. Giles, E.G. de Vries, S. de Jong, and S.T. Nawrocki Targeting TRAIL towards the clinic Curr. Drug Targets 12 2011 2079 2090
20. M.S. Merchant, J.I. Geller, K. Baird, A.J. Chou, S. Galli, A. Charles, M. Amaoko, E.H. Rhee, A. Price, L.H. Wexler, P.A. Meyers, B.C. Widemann, M. Tsokos, and C.L. Mackall Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors J. Clin. Oncol. 30 2012 4141 4147
21. A.I. Minchinton, and I.F. Tannock Drug penetration in solid tumours Nat. Rev. Cancer 6 2006 583 592
22. N. Muller, B. Schneider, K. Pfizenmaier, and H. Wajant Superior serum half life of albumin tagged TNF ligands Biochem. Biophys. Res. Commun. 396 2010 793 799
23. R.M. Pitti, S.A. Marsters, S. Ruppert, C.J. Donahue, A. Moore, and A. Ashkenazi Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family J. Biol. Chem. 271 1996 12687 12690
24. M. Plasilova, J. Zivny, J. Jelinek, R. Neuwirtova, J. Cermak, E. Necas, L. Andera, and T. Stopka TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors Leukemia 16 2002 67 73
25. J. Qin, V. Chaturvedi, B. Bonish, and B.J. Nickoloff Avoiding premature apoptosis of normal epidermal cells Nat. Med. 7 2001 385 386
26. D.V. Rozanov, A.Y. Savinov, V.S. Golubkov, O.L. Rozanova, T.I. Postnova, E.A. Sergienko, S. Vasile, A.E. Aleshin, M.F. Rega, M. Pellecchia, and A.Y. Strongin Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells Mol. Cancer Ther. 8 2009 1515 1525
27. J.C. Soria, Z. Mark, P. Zatloukal, B. Szima, I. Albert, E. Juhasz, J.L. Pujol, J. Kozielski, N. Baker, D. Smethurst, Y.J. Hei, A. Ashkenazi, H. Stern, L. Amler, Y. Pan, and F. Blackhall Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer J. Clin. Oncol. 29 2011 4442 4451
28. D.W. Stuckey, and K. Shah TRAIL on trial: preclinical advances in cancer therapy Trends Mol. Med. 19 2013 685 694
29. A. Thorburn Death receptor-induced cell killing Cell Signal 16 2004 139 144
30. C.C. Valley, A.K. Lewis, D.J. Mudaliar, J.D. Perlmutter, A.R. Braun, C.B. Karim, D.D. Thomas, J.R. Brody, and J.N. Sachs Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized J. Biol. Chem. 287 2012 21265 21278
31. H.A. Wakelee, A. Patnaik, B.I. Sikic, M. Mita, N.L. Fox, R. Miceli, S.J. Ullrich, G.A. Fisher, and A.W. Tolcher Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors Ann. Oncol. 21 2010 376 381
32. H. Walczak, R.E. Miller, K. Ariail, B. Gliniak, T.S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, C. Smith, P. Smolak, R.G. Goodwin, C.T. Rauch, J.C. Schuh, and D.H. Lynch Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo Nat. Med. 5 1999 157 163
33. H. Wang, J.S. Davis, and X. Wu Immunoglobulin Fc domain fusion to TRAIL significantly prolongs its plasma half-life and enhances its anti-tumor activity Mol. Cancer Ther 2014
34. S. Wang The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway Oncogene 27 2008 6207 6215
35. S.R. Wiley, K. Schooley, P.J. Smolak, W.S. Din, C.P. Huang, J.K. Nicholl, G.R. Sutherland, T.D. Smith, C. Rauch, and C.A. Smith Identification and characterization of a new member of the TNF family that induces apoptosis Immunity 3 1995 673 682
36. Y.S. Youn, M.J. Shin, S.Y. Chae, C.H. Jin, T.H. Kim, and K.C. Lee Biological and physicochemical evaluation of the conformational stability of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) Biotechnol. Lett. 29 2007 713 721
37. A. Younes, J.M. Vose, A.D. Zelenetz, M.R. Smith, H.A. Burris, S.M. Ansell, J. Klein, W. Halpern, R. Miceli, E. Kumm, N.L. Fox, and M.S. Czuczman A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkins lymphoma Br. J. Cancer 103 2010 1783 1787